Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Revelation Biosciences ( (REVB) ) has shared an announcement.
On May 23, 2025, George Tidmarsh, M.D., Ph.D., resigned from the Board of Directors of Revelation Biosciences, Inc., reducing the board size from five to four members. His resignation was not due to any disagreements with the company but to avoid potential conflicts of interest as he takes on a new role at Stanford University. The company expressed gratitude for his contributions over the past five years and reclassified Lakhmir Chawla, M.D., as a Class C Director.
The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to improve patient outcomes using its proprietary formulation Gemini. The company is engaged in multiple programs evaluating Gemini for various medical conditions, including post-burn and post-surgical infections, acute kidney injury, and chronic kidney disease.
Average Trading Volume: 111,877
Technical Sentiment Signal: Sell
Current Market Cap: $2.19M
See more data about REVB stock on TipRanks’ Stock Analysis page.